# Genmab

> Genmab is a Copenhagen-based biotechnology company that engineers antibody medicines for cancer and other serious diseases. It built a durable royalty business by licensing discoveries such as daratumumab, the molecule behind J&J's DARZALEX, then used that cash engine to become a more integrated drug developer and seller. Its four proprietary antibody platforms, partnered medicines, commercial products EPKINLY and Tivdak, and acquired late-stage programs place it between a specialist antibody foundry and a global oncology company.

- **Founded:** 1999
- **Headquarters:** Copenhagen, Denmark
- **Founders:** Jan G. J. van de Winkel (Co-founder; President and CEO), Lisa Drakeman (Co-founder; founding CEO), Florian Schönharting (Co-founder and early investor)
- **Team size:** Approximately 2,700 employees
- **Products:** DARZALEX / DARZALEX FASPRO, EPKINLY / TEPKINLY, Tivdak, Kesimpta, DuoBody
- **Notable:** Eight approved medicines incorporate Genmab innovation as of 2026., Roughly 20 compounds incorporating Genmab innovation were in clinical development in 2026., DARZALEX global net sales reported by J&J reached $14.351 billion in 2025.

## Products & services

- **DARZALEX / DARZALEX FASPRO** — Daratumumab-based multiple myeloma therapies commercialized worldwide by J&J; Genmab receives royalties.
- **EPKINLY / TEPKINLY** — Epcoritamab, a CD3xCD20 bispecific antibody for certain relapsed or refractory B-cell lymphomas, developed and commercialized with AbbVie.
- **Tivdak** — Tisotumab vedotin, an antibody-drug conjugate for previously treated recurrent or metastatic cervical cancer, partnered with Pfizer.
- **Kesimpta** — Ofatumumab for relapsing multiple sclerosis, commercialized by Novartis with royalties to Genmab.
- **DuoBody** — A platform for creating bispecific antibodies that can engage two targets or pathways.
- **HexaBody** — An antibody engineering platform designed to enhance antibody clustering and complement-mediated killing.
- **DuoHexaBody** — A platform combining bispecific targeting with enhanced, target-mediated hexamerization.
- **HexElect** — A paired-antibody platform intended to increase potency selectively on cells expressing two targets while limiting toxicity.
- **Petosemtamab** — A late-stage bispecific antibody candidate acquired with Merus and in Phase 3 development for head and neck cancer.
- **Rinatabart sesutecan (Rina-S)** — An investigational folate receptor alpha-directed antibody-drug conjugate added through the ProfoundBio acquisition.

## Achievements

- Eight approved medicines incorporate Genmab innovation as of 2026.
- Roughly 20 compounds incorporating Genmab innovation were in clinical development in 2026.
- DARZALEX global net sales reported by J&J reached $14.351 billion in 2025.
- Genmab revenue reached $3.720 billion in 2025, up 19% year over year.
- EPKINLY/TEPKINLY global net sales reached $468 million in 2025, up 67% year over year.
- Genmab completed its approximately $8.0 billion acquisition of Merus in December 2025.
- The company became dual-listed after its 2019 Nasdaq U.S. ADS offering, adding to its Copenhagen listing.
- Genmab marked its 25th anniversary in February 2024.

## Latest updates

- **2026-07** — J&J reported $4.207 billion in second-quarter DARZALEX net sales, on which Genmab receives worldwide royalties.
- **2026-07** — The European Commission approved TEPKINLY in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.
- **2026-06** — A Phase 3 trial of epcoritamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma met its progression-free-survival endpoint.
- **2026-05** — Genmab reiterated full-year 2026 revenue guidance of $4.065 billion to $4.395 billion in its first-quarter report.
- **2026-02** — Genmab reported 2025 revenue of $3.720 billion and projected 2026 revenue growth led by royalties and product sales.
- **2025-12** — Genmab completed the tender offer for Merus, adding the late-stage petosemtamab program.

## Links

- Website: https://www.genmab.com/
- LinkedIn: https://www.linkedin.com/company/genmab
- Twitter/X: https://twitter.com/genmab
- YouTube: https://www.youtube.com/@genmab4484

---

Profile page: https://yespress.io/genmab
Published by YesPress — https://yespress.io
Last updated: 2026-08-11